Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model.
about
Sugarbaker procedure for pseudomyxoma peritoneiA new standard of care for the management of peritoneal surface malignancySurgical technology and pharmacology of hyperthermic perioperative chemotherapyChemotherapy-induced late transgenerational effects in miceUsing pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer.Peritoneal carcinomatosis of colorectal origin.Hyperthermic intraperitoneal chemotherapy: Rationale and techniqueIntraperitoneal chemotherapy for colorectal cancer.Perioperative intraperitoneal chemotherapy for peritoneal surface malignancyBypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control.Administration of substances to laboratory animals: routes of administration and factors to consider.Pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patientsHyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional ChemotherapyLaboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy.Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach.Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy.Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity.Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics.Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.Intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis: review of animal models.Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells.DNA hydrogel delivery vehicle for light-triggered and synergistic cancer therapy.Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis.Potential metabolomic biomarkers for evaluation of adriamycin efficacy using a urinary 1H-NMR spectroscopy.Pharmacokinetic study of perioperative intravenous Ifosfamide.Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer.Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis.Principles and Innovations in Peritoneal Surface Malignancy Treatment.Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer.Light-responsible DNA hydrogel–gold nanoparticle assembly for synergistic cancer therapy
P2860
Q24245207-7A965147-5E16-4AB9-92C3-6E01BB487006Q24626790-F7A793A6-BAC0-44CA-9FF2-0EF9D145F33DQ26768405-B63485C5-F41D-4226-8B69-08EDB2FC1DD8Q28477444-F8556C71-F701-4D34-8F2B-CDC547ADB563Q33416610-4AA8C365-E5BA-4A48-A5F9-0FBCEF1A145BQ33994410-3F9D6A20-3967-4967-9C9D-C59FD211F525Q34391090-893F3460-6D6C-403F-BE49-29E089C2C182Q34391107-33C8BB91-FD48-4C26-914F-58D3FC4C4045Q34469122-5632A20A-1F6E-4C5A-ADFB-0F87A90892DAQ34690528-BD78B709-4D87-49F7-B2F3-5776D07B07ABQ35284185-B6759E8A-92EC-4076-AD88-30BFECE472C2Q35295915-FBDED15F-1849-4AB3-89B8-D637891B6866Q36063487-68037D17-8C86-4E33-AF8D-6DBC0F9A5008Q36758933-14AEE1D3-8C8E-47C0-AED7-097F01BD36FDQ36911440-499AD93D-3613-498D-96D6-5FEFE1B49813Q37534736-AD5C5947-3CD9-4FB5-A932-6E51A11051CEQ37662806-6891DD34-14A1-47E7-B3BF-042AA64599CDQ37821289-34260F66-5FF3-4DE6-9980-1D69A6958BE3Q37895575-8F15FE93-4995-4F82-B67A-D4DF81BD4E5CQ37987561-EF18DEBB-E602-4A9B-81ED-CA4D9BED2F52Q37993908-493F3BA8-5555-4D56-A8DF-90BC1451DADDQ38152303-0837A24C-205D-4A71-A44D-D8F870719ACDQ38866435-EFDA31E3-9D7C-4D96-996A-937ECE35E751Q38877029-9627D77D-AD34-4620-8E8A-8B7928F144C2Q39078137-DE492C2E-A975-4310-B078-86AD0C1C8D25Q39316748-CD8B9987-FBEC-416C-974C-92DCF1667EA6Q40583827-F791ED14-63CB-446E-887A-6830F3489CA9Q41132998-2D34919E-11E1-457C-A99C-ECC7DD6F2BB4Q44949607-869AEDE3-CE79-4DBA-9209-4DB754880B0FQ47166165-560767D1-B5B4-4AFB-8EBA-EE72FC6F7BDEQ51825453-7DE38041-90A5-42BC-A1E6-38601B0AFA35Q59197905-D31C63FF-2F80-479B-83EA-79170C890300
P2860
Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Hyperthermic intraperitoneal d ...... e distribution in a rat model.
@en
type
label
Hyperthermic intraperitoneal d ...... e distribution in a rat model.
@en
prefLabel
Hyperthermic intraperitoneal d ...... e distribution in a rat model.
@en
P2093
P356
P1476
Hyperthermic intraperitoneal d ...... e distribution in a rat model.
@en
P2093
P2888
P304
P356
10.1007/S002800050721
P577
1998-01-01T00:00:00Z
P6179
1044972615